Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. - Wikidata - awgldk - TriplyDB

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

http://www.wikidata.org/entity/Q38376308

about

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib Targeted therapy for advanced renal cell carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Targeted therapies and the treatment of non-clear cell renal cell carcinoma Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Hypertension in patients with cancer Individualising treatment choices in a crowded treatment algorithm Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Targeted therapies for non-clear renal cell carcinoma.The prospects of pazopanib in advanced renal cell carcinoma.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Targeting the mTOR pathway in Chromophobe Kidney Cancer.Current status of targeted therapy for advanced renal cell carcinoma Novel agents in renal carcinoma: a reality check.Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis Experience with sorafenib in the treatment of advanced renal cell carcinoma.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study

P2860

Q21261282-FC630524-1FBB-4660-BD6C-84E34F275ED4 Q24242946-5BC0EBF1-E22C-4163-923B-D2D500CEDBC9 Q26772206-87C8EA08-795E-4485-9657-05093861D130 Q26782585-9F24381F-41AF-4D76-A143-44E6ADC97BBF Q26995391-9719A263-1508-4064-A4B8-52A9B0430395 Q27003304-B698B7C9-EAFF-42F2-B4CA-31C7DF7D58B7 Q27003980-90737FB1-24FD-43D3-846D-4F659F7E8322 Q27023669-9A71518C-4843-483A-9DA3-E0D4D572D16A Q27851979-B43EEFEF-E1E3-4581-92B8-C21D8B36EBC4 Q28077050-DA808C8A-9F99-4F7F-9822-A85F6482A241 Q28547506-1586252B-039B-4BD5-9546-EB5A6E452813 Q30382892-BFF5D45A-CAC1-4CE1-9674-BA42CD8488C3 Q30486440-F9C04FB2-462F-4853-A4B9-F9290B4E5156 Q33166002-670FCAA0-5554-4F55-AF88-8F54C1D549BD Q33423740-496B2C57-A794-4BC0-B841-ACE409C2498B Q33577856-2CB0CF6F-3DB4-4386-B4FF-5CA9CFC02E02 Q33642302-18633DB2-BCE2-482E-B54F-2AD8208D86FC Q33754122-00A23D96-4196-4AD8-942F-616A88110812 Q33854836-81400C9E-C7A9-45E2-A8B2-DF72A9DF41CB Q34094975-D872C4E0-B839-4E77-9E5F-DAE29FA3B0AB Q34152578-7D578796-8398-40CF-9150-C73B0A707F0D Q34206531-BB8E4083-95CD-4C24-B8AC-27F0984ECF5C Q34351372-0AB7B493-D1A7-4F11-959A-84E8EEF43A1B Q34412479-E8A9FB7F-8CBB-4FA2-AA2E-60DDCAD8E30F Q34656393-EE32A3C3-32DA-4BB2-B62F-50E057B61E3A Q34657590-B370DF35-B84A-4CC6-B83D-FE28B0249097 Q34660431-AB35C9E1-F2E0-4112-B83C-73DCAC919C8A Q35063752-F48E50F8-E76E-4206-A058-338DE786A888 Q35584182-08A37375-F25D-401D-A7BE-AEBA2D4306B0 Q35591889-58A6ED33-0EDC-4469-81E9-FC574A4EFA8A Q35872175-A1212F5B-E478-4EFE-861B-4AE7BCAAC178 Q35903850-15E04436-BABF-4DC1-9D0D-D2D601579615 Q36061173-4158F20E-7939-4401-B145-B9ACCCAFA2B1 Q36072803-DFC3B53D-0CBE-4D8E-8991-7EE31C548932 Q36137398-F6FB08B7-4EC2-4359-846D-B3E071DCF06E Q36182819-3649A87A-B593-437F-B1A8-2FF960D53C9D Q36241010-B34202B2-5491-47A9-AC18-9050F43E2033 Q36251480-57FE3554-015A-491A-99C5-D75E92E2E575 Q36379345-716E4CDF-1026-4ACD-89BB-8C87C9F7A09C Q36546814-88D878B0-14D6-4644-BB5E-564B29C916FA

P2860

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

http://www.wikidata.org/entity/Q38376308

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Safety and efficacy results of ...... cess program in North America.

@en

type

label

Safety and efficacy results of ...... cess program in North America.

@en

prefLabel

Safety and efficacy results of ...... cess program in North America.

@en

P1433

Q38376308-2EA4DB4B-AF1A-41A3-A4D1-93ECC20FFBF2

P1476

Q38376308-D0FDA5FE-3091-412A-9B39-D36A873A2F98

P2093

Q38376308-08574B83-5695-4870-8F4A-19D1F2C40828

Q38376308-0FC664D5-A180-49A8-B2F3-621CF24D1D3D

Q38376308-11FB2D77-36F7-41F1-BB2D-B5B4AFF92218

Q38376308-34A83C9A-4BBB-4F2C-91E8-1A7CC3B17E3D

Q38376308-3999CC7E-08CE-4C68-8494-6EF7B0C93749

Q38376308-4296216E-BA10-45BB-ADD7-D3BFBB66073A

Q38376308-43B62D38-B2E8-4216-B2C1-35180C0F9A9F

Q38376308-51B565FF-928B-499A-8652-2B73082DF273

Q38376308-631F9738-73FD-4702-9E11-8F86B422C2FF

Q38376308-84320D1C-C30D-49A8-A3E8-C93EC162153F

P304

Q38376308-9495A7E8-0B0D-4C8A-A205-C6FB5F923F76

P31

Q38376308-1620B50E-E108-4BDB-AE5F-12EAE6103179

P356

Q38376308-085A30A9-CFFE-46F8-B5EC-7621704FF5AF

P407

Q38376308-0C63274C-73F0-46B4-AD05-CE71FD4048C7

P433

Q38376308-CA9CFB71-7673-4E63-89A6-7410B7AE5FC0

P478

Q38376308-BEB63BA1-739C-4963-8A9F-5AEAA1A58003

P50

Q38376308-FB8182B6-0A49-4AD5-A944-7075DB1A742E

P577

Q38376308-9C518515-BD75-4EBE-80F4-AAD34812B6E3

P5875

Q38376308-CF734675-D66C-480C-A4AF-C82C3CEED2CC

P698

Q38376308-5E9A70B7-3A12-4B06-B3AB-C91A8A0A93CA

P356

P1433

P1476

Safety and efficacy results of ...... cess program in North America.

@en

P2093

ARCCS Study Investigators

http://www.w3.org/2001/XMLSchema#string

Brendan D Curti

http://www.w3.org/2001/XMLSchema#string

Charles A Henderson

http://www.w3.org/2001/XMLSchema#string

Chenghua Xia

http://www.w3.org/2001/XMLSchema#string

Christopher W Ryan

http://www.w3.org/2001/XMLSchema#string

David F McDermott

http://www.w3.org/2001/XMLSchema#string

Harry A Drabkin

http://www.w3.org/2001/XMLSchema#string

Janice P Dutcher

http://www.w3.org/2001/XMLSchema#string

Jeffrey R George

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

P304

1272-1280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24864

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

John D Hainsworth

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41042104

http://www.w3.org/2001/XMLSchema#string

P698

20082451

http://www.w3.org/2001/XMLSchema#string